Join
Live feed
·
PRReleasevia Quantisnow
Better Therapeutics Inc. logo

Better Therapeutics Completes Pivotal Trial of BT-001 for Type 2 Diabetes and Announces Positive Secondary Endpoint Results Following the Earlier Announcement of Positive Primary Endpoint Results

ByQuantisnow·Wall Street's wire, on your screen.
BTTX· Better Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BTTX (Better Therapeutics Inc.) and more on Quantisnow.